<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01777685</url>
  </required_header>
  <id_info>
    <org_study_id>PPT3</org_study_id>
    <nct_id>NCT01777685</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride After Oral Administration to Healthy Volunteers</brief_title>
  <acronym>SUL</acronym>
  <official_title>Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study was adopted to evaluate the pharmacokinetics of sulpiride after oral
      administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study was adopted to evaluate the pharmacokinetics of sulpiride after
      administration of single oral doses of 50 mg in an open-label, one-way study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>•Assessment of the bioequivalence of the oral suspension formulation, the oral solution formulation, and the marketed tablet formulation of levofloxacin, on Days 1, 2, and 3, using the marketed tablet as the reference. Pharmacokinetics of sulpiride</measure>
    <time_frame>The pharmacokinetic analysis is done after blood sampling</time_frame>
    <description>Assessment of the pharmacokinetics using compartmental and non compartmental analysis of sulpiride after oral administration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>sulpiride 50 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulpiride</intervention_name>
    <arm_group_label>sulpiride 50 mg</arm_group_label>
    <other_name>Dogmatil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old and not more than 45 healthy male volunteers

          -  Actual weight no more than ± 30% from ideal body weight based on sex, height, and body
             frame

          -  Who had passed all the screening parameters

          -  Free of any drug exposure known to interfere with the pharmacokinetics or assay of
             sulpiride for at least 10 days prior to the study

          -  Who had to be able to communicate effectively with study personnel, be literate, and
             able to give consent.

        Exclusion Criteria:

          -  A clinically significant abnormal physical exam, medical history, or laboratory
             studies If they showed a sitting SBP of &gt;140 or &lt;100 mmHg, DBP &gt; 90 or &lt;60mm Hg, or a
             pulse rate of &gt; 95 or &lt; 50 beats/min at screening A history of serious intolerance,
             allergy, or sensitivity to fexofenadine The use of any prescription drug within the
             previous month or use of any over-the-counter medication (with the exception of
             acetaminophen) within the past 14 days A history of blood dyscrasias A history of
             alcohol or drug abuse within the past year Donation of blood during the 8 weeks prior
             to the study or plans to donate blood during or within 8 weeks of completing the study
             Unable to tolerate vein puncture and multiple blood samplings Any surgical/medical
             condition that might alter drug absorption, distribution, metabolism, or excretion
             Cannot follow instructions, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmaceutics Department, Faculty of Pharmacy, Damanhour University</name>
      <address>
        <city>Damanhour</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sulpiride</keyword>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

